Effects of microinjection of the D2 dopamine antagonist raclopride into the ventral tegmental area on ethanol and sucrose self-administration.
From previous microinjection studies, a reciprocal feedback between the nucleus accumbens and the ventral tegmental area (VTA) has been implicated in the reinforcing stimulus actions of ethanol and sucrose. In these studies, the effects of self administration of ethanol or sucrose solutions on maintained responding were similar when a dopamine antagonist was injected in the nucleus accumbens or a dopamine agonist was injected into the VTA. Our study was performed to determine if the effects on responding that had been observed when a dopamine agonist was injected into the nucleus accumbens would occur after an injection of a dopamine antagonist into the VTA. Male, Long-Evans rats were initially trained to lever press using either 10% ethanol or 75% sucrose solutions as the reinforcers. Bilateral guide cannulae were implanted to allow microinjection into the VTA of differing doses of the dopamine D2 antagonist, raclopride. Only at the highest dose tested (10 microg) was any effect observed on responding maintained by either reinforcer. The effect was minimal and different from that observed after the microinjection of a dopamine agonist into the nucleus accumbens. This suggests that either the actions of the nucleus accumbens agonist manipulation involved other processes or that the level of enhanced dopamine release in the nucleus accumbens from the VTA antagonist injection was not sufficient to mimic the effect of the nucleus accumbens agonist injections.
Samson
H H
HH
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1983, USA. hsamson@medcneter.wpmail.wfu.edu
Chappell
A M
AM
D000428:Alcohol Drinking / Q000503:physiopathology*; D000818:Animals; D003216:Conditioning, Operant / Q000187:drug effects; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D008297:Male; D008845:Microinjections; D020891:Raclopride; D051381:Rats; D020318:Rats, Long-Evans; D012457:Salicylamides / Q000008:administration & dosage / Q000494:pharmacology*; D012646:Self Administration; D013395:Sucrose / Q000008:administration & dosage / Q000494:pharmacology*; D017557:Ventral Tegmental Area / Q000187:drug effects / Q000502:physiology*
D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D012457:Salicylamides; D020891:Raclopride; D013395:Sucrose